Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.60 |
| ▸ | PI4KA | P42356 | 2/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19774740 | 1.00 | ADORA2A (0.78) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL465643 | 1.00 | ADORA2A (0.78) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL17117141 | 1.00 | ADORA2A (0.78) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL11896815 | 1.00 | ADORA2A (0.78) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL29722667 | 1.00 | ADORA2A (0.78) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL13951444 | 1.00 | ADORA2A (0.78) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL13929067 | 1.00 | ADORA2A (0.78) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL19762330 | 1.00 | ADORA2A (0.78) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL13672370 | 1.00 | ADORA2A (0.78) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL14429199 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4032897-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Gilead Pharmasset LLC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, LTD. (BB) | 2019-10-17 | — | — | US | disclosed |
| EP-3521297-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Gilead Pharmasset LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2604620-A1 | Modified fluorinated nucleoside analogues | Gilead Pharmasset LLC (US) | 2013-06-19 | — | — | EP | disclosed |
| US-8415322-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415322-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415322-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120245335-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245335-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2345658-A1 | Modified fluorinated nucleoside analogues | Pharmasset, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2345661-A1 | Modified fluorinated nucleoside analogues | Pharmasset, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7429572-B2 | Modified fluorinated nucleoside analogues | PHARMASSET, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429572-B2 | Modified fluorinated nucleoside analogues | PHARMASSET, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | GILEAD SCIENCES, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885PI4KA 1353/4885 |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885PI4KA 1353/4885 |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885PI4KA 1353/4885 |
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885PI4KA 1353/4885 |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885PI4KA 1353/4885 |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885PI4KA 1353/4885 |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885PI4KA 1353/4885 |
| US-20120245335-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885PI4KA 1353/4885 |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885PI4KA 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.